Minted: - / 5000

3592 Lubazodone
7c13854b09c7c3e3fd63f8affd5eeac427c209c4a78e246a83d272381b5dae37

Properties

Background

Orange
Bottle

Blue
Cap

Red
Syringe

Purple
Bubbles
No
Drops
No
Label
Bacterium

Chemistry

Formula
C14H18FNO2
Carbon
14
Polarity
Neutral

Lubazodone (developmental code names YM-992, YM-35995) is an experimental antidepressant which was under development by Yamanouchi for the treatment for major depressive disorder in the late 1990s and early 2000s but was never marketed. It acts as a serotonin reuptake inhibitor (K_i for = 21 nM) and 5-HT_2A receptor antagonist (K_i = 86 nM), and hence has the profile of a serotonin antagonist and reuptake inhibitor (SARI). The drug has good selectivity against a range of other monoamine receptors, with its next highest affinities being for the α₁-adrenergic receptor (K_i = 200 nM) and the 5-HT_2C receptor (K_i = 680 nM). Lubazodone is structurally related to trazodone and nefazodone, but is a stronger serotonin reuptake inhibitor and weaker as a 5-HT_2A receptor antagonist in comparison to them and is more balanced in its actions as a SARI. It reached phase II clinical trials for depression, but development was discontinued in 2001 reportedly due to the "erosion of the market in the United States".

From Wikipedia, the free encyclopedia. License: CC BY-SA.